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Summary Mice grafted with the 3LL (Lewis lung) carcinoma exhibit immune suppression: spleen cells showed decreased spontaneous
interleukin 2 (IL-2) production and T-CD4+ and T-CD8+ lymphocyte populations; in addition the polyamine content in the spleen was
increased. By treating the mice with a polyamine-deficient diet containing neomycin, metronidazole and inhibitors of ornithine decarboxylase
and polyamine oxydase, tumour growth was reduced and the immune abnormalities were reversed. The spleen cells overproduced IL-2 by
reducing exogenous sources of polyamines, but total blockade of all major polyamine sources was necessary to obtain an optimal effect both
on IL-2 production and on spleen polyamine content. Irrespective of whether polyamine deprivation was started at an early or at an advanced
stage of tumour growth, T-lymphocyte populations were restored to normal values, demonstrating that polyamine deprivation not only
prevents tumour-induced immune suppression, but reverses established immunological disorders. In contrast to what was observed
regarding IL-2 production by spleen cells and natural killer (NK) cell activity, the polyamine oxidase (PAO) inhibitor did not enhance the
number of T lymphocytes. These findings are consistent with a direct effect of the polyamines on immune effector cell metabolism. They
suggest an important role of the gastrointestinal polyamines and of PAO activity in the regulation of IL-2 production.
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The natural polyamines putrescine (NH2(CH2)4NH2), spermidine
(NH2(CH2)3NH(CH2)4NH2) and spermine (NH2(CH2)3NH(CH2)4
NH(CH2)3NH2) are ubiquitous cellular components that play an
important role in proliferation and differentiation (Tabor and
Tabor, 1984; Pegg, 1986; Heby, 1989). The first step in polyamine
biosynthesis is the decarboxylation of omithine by omithine
decarboxylase (ODC). Mitogen stimuli enhance ODC activity and
polyamine levels; in fast-dividing cancer cells polyamine metabo-
lism is increased (Pegg, 1988). The selective and irreversible inhi-
bition of ODC by D,L-2-(difluoromethyl)omithine (DFMO,
Eflomithine) inhibits tumour cell proliferation in culture (Mamont
et al, 1978). But in vivo, the anti-tumoral effect of DFMO was
limited. This failure was partly because of the availability of
polyamines from tissues, the diet and the intestinal microflora
(Hessels et al, 1989; Sarhan et al, 1989). Tumour progression is
prevented in animals treated with a polyamine-deficient diet,
containing antibiotics for the decontamination of the gastro-
intestinal tract, inhibitors ofpolyamine biosynthesis and the inter-
conversion pathway (ODC and polyamine oxidase inhibitors)
(Seiler et al, 1990; Hessels et al, 1991; Moulinoux et al, 1991a,b;
Quemener et al, 1992).
The failure of the immune system to eliminate established
cancer is partly because of the immune suppression induced by
the tumour. In view of the importance of cell proliferation and
differentiation in cell-mediated immune responses, polyamine
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deprivation, in addition to its inhibitory effect on tumour cell
growth, could modulate immune responses of tumour-bearing
mice. We have previously shown that the blockade of all major
endogenous and exogenous polyamine sources, necessary to
obtain an optimal tumour growth inhibition, normalizes the cyto-
toxic activity ofnatural killer (NK) cells (Chamaillard et al, 1993).
Polyamines play important role in immune processes (see review
by Seiler and Atanassov, 1994). As inhibition of polyamine
biosynthesis by DFMO stimulates T-lymphocyte IL-2 production
(Bowlin et al, 1987), it was of interest to know the influence
of total polyamine deprivation on IL-2 production in vivo. As
polyamine oxidation down-regulates IL-2 production in T
lymphocytes (Flescher et al, 1989), it was important to evaluate
the influence of a polyamine oxidase (PAO) inhibitor on the
immune response in vivo. The aim ofthis study was to analyse the
effects in vivo of the different components of polyamine depriva-
tion on spontaneous IL-2 production and lymphocyte populations
in mice grafted with the 3LL Lewis lung carcinoma.
MATERIALS AND METHODS
Chemicals and drugs
Metronidazole was from Rh6ne-Poulenc (Paris, France); penicillin
and streptomycin from Biomerieux (Marcy-1'Etoile, France);
[6-3H]thymidine (sp. act.: 109 mCi mg-', 1 mCi ml-') from
ICN Radiochemicals (Les Ulis, France); recombinant mouse
IL-2 and monoclonal rat anti-mouse IL-4 antibody from
Genzyme (Cambridge, USA); and RIA PGE2 kit from Amersham
(Les Ulis, France). Standard rodent chow was from Pietrement
(Provins, France). Polyamine-deficient chow (PDC), D,L-2(di-
fluoromethyl)omithine (DFMO; Eflomithine, MDL 71782) and
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N',N4-Bis-(2,3-butadienyl)-putrescine dihydrochloride (MDL
72527) were kind gifts from Marion Merrell Dow Research
Institute (Strasbourg, France). Neomycin, anti-mouse CD4 R-
phycoerythrin (anti-CD4-PE), anti-mouse CD8a quantum red
(anti-CD8-QR), anti-mouse CD3 fluorescein isothiocyanate (anti-
CD3-FITC), anti-mouse CD25 R-phycoerythrin (anti-CD25-PE)
antibodies, mouse isotype controls and usual laboratory chemicals
were from Sigma C (St Louis, MO, USA).
Cell culture
Culture reagents were from Flow Laboratories (Irvine, CA, USA).
The 3LL Lewis lung carcinoma cell line was maintained in RPMI-
1640 medium supplemented with 2 mM L-glutamine, penicillin
(100 U ml-'), streptomycin (50 gg ml-') and 10% heat-inactivated
fetal calf serum (supplemented medium) at 37°C under a 5%
carbon dioxide atmosphere. The murine IL-2-dependentT-cell line
(CTLL2) was maintained in the same medium, containing in addi-
tion 1 mM Hepes, 2.5 mm sodium pyruvate, 50 gM P-mercapto-
ethanol and 0.8 U ml-' recombinant IL-2.
Mice and tumours
Viable 3LL Lewis lung carcinoma cells (5 x 105) were injected
intramuscularly into the hind legs of 6- to 8-week-old Fl-
C57BL6/DBA2. Tumour volumes were measured as previously
reported (Moulinoux et al, 1984). Animals were kept under stan-
dardized conditions: 20'C, 12 h light/dark cycle with food and
water ad libitum. All animal procedures were performed strictly
according to institutional guidelines.
Treatments
Animals received ad libitum a polyamine-deficient chow (PDC)
(Seiler et al, 1990), supplemented with neomycin (N) (2 g kg-')
and metronidazole (M) (34 mg kg-') (diet designated NM-PDC)
and with DFMO (30 g kg-') (drug containing polyamine-deficient
chow: DC-PDC). When An,N4-bis-(2,3-butadienyl)putrescine
(MDL 72527, PAO inhibitor) (500 mg kg-') was added to DC-
PDC, the diet was designated DC-PDC+. Controls received stan-
dard chow (SC) ad libitum; other groups received SC and DFMO
orMDL 72527 in the drinking water atadose corresponding to the
DC-PDC+ treatment [3% (w/v) DFMO, 0.05% (w/v) MDL
72527]. All animals received drinking fluid ad libitum. For the
composition and designation ofvarious treatments see Table 1.
Treatments were given for 6 days either 1 week after tumour
cell inoculation, when all mice had developed palpable tumours
(0.1 cm3 - early stage of tumour development), or 2 weeks after
graft (0.8 cm3 -advanced stage oftumour development) (Figure 1).
Animals were sacrificed after 6 days of treatment. Healthy mice
and untreated 3LL grafted mice were sacrificed at the same time in
each experiment. All experiments were carried out three times.
Preparation of spleen cells
Spleens were removed under sterile conditions, mechanically
dissociated in RPMI-1640 medium, and filtered through sterile
gauze to remove debris and to obtain single cell suspensions as
previously described (Chamaillard et al, 1993). Erythrocytes were
lysed by 0.17 M ammonium chloride, and the residual cells were
washed and counted; viability was determined by trypan blue
exclusion.
Spontaneous IL-2 production
Spleen cells (107 cells ml-') were incubated in supplemented
medium for 48 h at 37°C in 24-well tissue culture plates. Culture
supernatants were collected and spontaneous IL-2 production was
assessed by a bioassay measuring the proliferation of the CTLL2
cells according to the method of Gillis et al (1978). The CTLL2
cells were washed free of growth medium (exogenous IL-2) and
resuspended in culture medium at a concentration of4 x 104 cells
ml-'. Cells were distributed in 96-well microplates (0.1 ml) and
0.1 ml ofdifferent dilutions ofsupernatants were added. The cells
were incubated for48 h at 370C - 5% carbon dioxide - and pulsed
with 1 ,uCi well-' [6-3H]thymidine for the final 8 h ofculture. The
labelled cells were harvested using a semiautomatic cell harvester
(Skatron) and [6-3H]thymidine incorporation measured using a
beta-scintillation counter (Packard). IL-2 units were defined by the
dilution ofrecombinant IL-2 required for 50% maximal prolifera-
tion. Because the proliferation of CTLL2 cell line is also IL-4
dependent, one assay was done in the presence of neutralizing
anti-mouse IL-4 antibody (1.5 gg ml-') during the culture to
distinguish IL-2 from IL-4 activity.
Identification of splenic T-cell populations
The CD4 and CD8 T-cell populations were identified by double
labelling, using anti-CD3-FITC/anti-CD4-PE and anti-CD3-
FITC/anti-CD8-QR. The T-CD8+ lymphocyte population,
expressing the IL-2 (a-chain) receptor (CD25), was determinedby
triple labelling with anti-CD3-FITC/anti-CD8-QRlanti-CD25-PE.
Spleen cells (0.5 x 106 cells) were suspended in PBS containing
1% bovine albumin and incubated for 30 min at 40C before
staining with 0.5 ,ig of the antibodies (or isotype control) for
30 min on ice. Cells were washed with 1 ml ofphosphate-buffered
saline (PBS) containing 0.5% bovine albumin, resuspended and
fixed in 3% formaldehyde in PBS. Flow cytometric analysis was
performed using a Coulter Epics Elite Flow Cytometer equipped
with an argon laser (excitation wavelength at 488 nm, 15 mW).
Green fluorescence was measured at 550 nm using long-pass
dichroic and 525 nm bandpass filters, yellow fluorescence at
600 nm using long-pass dichroic and 575 nm bandpass filters
and red fluorescence at 675 nm (bandpass filter). The mean of
fluorescence was expressed in arbitrary units.
Determination of prostaglandin E2 production
A prostaglandin E2 (PGE2)-dependent immune suppressor phase
has been described during the early phase of Lewis lung carci-
noma growth (Ippoliti et al, 1985; Young et al, 1985). For this
reason, the levels of PGE2 were determined in plasma. An
immunoassay using ['251]PGE2 as tracer was used. After dilutions
(1:20), 500 gl of samples was acidified with 12.5 pl of 2 N
hydrochloric acid (pH 3.5-4.5) and PGE2 was extracted twice with
500 ,l ofethyl acetate. Extracts were evaporated with a Speed Vac
Concentrator (Savant). In this assay system, it is necessary to
convert extracted PGE2 into an oxime and PGE2 was assessed by
radioimmunoassay procedure using a standard calibration curve
(0-1600 pg ml-').
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Table 1 Composition and designation of various treatments
Chow Abbreviations Drugs
Neomycin Metronidazole DFMO MDL 72527
(g kg- of drinking water orfood)
Standard chow
Controls
DFMO 30
MDL 72527 0.5
Polyamine-deficient chow
NM-PDC 2 0.034
DC-PDC 2 0.034 30
DC-PDC+ 2 0.034 30 0.5
Animals fed with standard chow received drugs in dnnking water. Animals fed
with polyamine deficient chow received drugs in the food.
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Figure 1 Effect of polyamine deprivation on tumour growth and splenic T-cell
populations. DC-PDC+ treatment was given either at an early stage of
tumour development (1 week after tumour cell inoculation, when all mice had
developed palpable tumours) or at an advanced stage of tumour
development (2 weeks after graft). Animals were sacrificed after 6 days of
treatment. Data are tumour volume and the percentage of cells expressing
CD3/CD4 (T-CD4+) and CD3/CD8 (T-CD8+) differentiation markers
(mean ± s.e.m. n = 11-15). *Significantly different from untreated tumour-
bearing mice 2 weeks after graft (P< 0.05)
Determination of polyamine concentrations
Spleen cells were prepared as described above after lysis of the
erythrocytes. A total of 106 spleen cells were sonicated in 1 ml of
ice-cold 5% perchloric acid. After dansylation, perchloric extracts
were submitted to HPLC separation as described previously
(Moulinoux et al, 1984).
Statistical analysis
The non-parametric Mann-Whitney ranking test was used to
determine statistical significance when comparing treated 3LL
mice with healthy or 3LL untreated mice.
RESULTS
Tumour growth inhibition
The growth of the 3LL carcinoma was significantly reduced by
feeding mice for 6 days with a PDC containing antibiotics and
inhibitors of polyamine metabolism (Table 2). Tumour growth
inhibition due to polyamine deprivation was observed when treat-
ment was started 1 or 2 weeks after graft (Table 2 and Figure 1).
Effects of polyamine deprivation on weight and
polyamine concentrations of the spleen and on PGE2
plasma concentration
Two weeks after tumour cell inoculation, the spleen weight ofmice
with tumour was about twice that of controls. The polyamine
concentration in the spleen cells oftumour-bearing mice was signif-
icantly increased (Table 2). After a treatment with DC-PDC or DC-
PDC+, spleen weight and polyamine concentrations were restored
to normal values. No significant difference was observed in the
plasma PGE2 levels ofhealthy or tumour-bearing mice (Table 2).
Effects of polyamine deprivation on spontaneous IL-2
production by spleen cells
Lymphocyte stimulation with agents such as concanavalin A has a
great effect on polyamine metabolism (for review see Seiler and
Atanassov, 1994). Therefore, no mitogens were used in our study.
Proliferation ofthe IL-2-dependent cell line CTLL2 was slow in the
presence ofthe supematant collected from the spleen-cell culture of
tumour-bearing mice (Figure 2). By contrast, IL-2 production by the
spleen cells of tumour-bearing mice treated with DC-PDC+ was
similar to that of healthy mice (Figure 2). The presence of anti-
mouse IL-4 antibody in our assay did not affect the proliferation of
the murine CTLL2. As shown in Table 3, DC-PDC+ treatment
increased IL-2 production in tumour-bearing mice 5.8 times. When
drugs and/or components ofDC-PDC+ were given separately, IL-2
levels increased but remained significantly lower than in healthy
controls. Nevertheless, increase in IL-2 production by depletion of
exogenous polyamines with NM-PDC, or by DC-PDC (without
MDL 72527), was significant when compared with cancerous
untreated mice (Table 3). DFMO did notadd any effect toNM-PDC.
When inhibitors ofpolyamine metabolism - DFMO or MDL 72527
- were given alone, the IL-2 production was slightly, but not signifi-
cantly, increased compared with untreated tumour-bearing mice.
Splenic T-lymphocyte populations
T-lymphocyte populations were decreased in the spleen of 3LL
bearing mice compared with healthy mice (Figure 1). Two weeks
after graft, CD3-positive cells (CD3+) and T-CD4+ lymphocytes
were similarly reduced by 30% while the T-CD8+ lymphocyte
population exhibited a 50% reduction (Table 4). Consequently, the
T-CD4+/T-CD8+ ratio in 3LL grafted mice increased compared
with healthy controls (Table 4). A significant decrease in the T-
CD8+CD25+ cell population was also observed (Table 5).
However, the relative percentage of T-CD8+CD25+ cells in the
total T-CD8+ population remained unchanged: in treated or
untreated cancerous mice around 22% of the T-CD8+ cells were
CD25 positive, 17% in healthy controls. No difference was
observed in the intensity ofthe CD25 labelling (Table 5).
When DC-PDC or DC-PDC+ treatment was given at an early
stage of tumour development (1 week after graft), T-CD4+
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Table 2 Effects of polyamine deprivation on tumour growth, on prostaglandin E2 (PGE2) production, on spleen weight and splenic polyamine content.
Treatment Tumour volume PGE2 Spleen weight Polyamine concentrations
(cm3) (pg mi-' plasma) (mg) (pmol 10-6 spleen cells)
Putrescine Spermidine Spermine
Healthy controls 730 ± 100 75± 15 66± 22 241 ± 31 232± 33
3LL controls 0.57 ± 0.38 850 ± 90 142± 44a 103± 26a 412±91 a 328± 66a
DC-PDC 0.25± 0.14b 1190 ±120 85± 13b 69± 13b 238± 23b 265± 23
DC-PDC+ 0.22+ 0.1Ob 995±155 85± 17b 45 ±llb 232± 25b 285± 29
Data were significantly different from healthy controls (ap< 0.05) and from untreated 3LL grafted mice (bp< 0.05). Treatments were started at an early stage of
tumour development (1 week after graft). Data are the tumour volume, plasma concentration of PGE2 and spleen weight after 6 days of treatment. The
polyamine concentrations were determined on 106 spleen cells. Mean of five values ± s.d.
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Figure 2 Proliferation of the IL-2-dependent CTLL2 cell line in the
presence of spleen cell supernatants of polyamine deprived mice. Spleen
cells were collected from healthy, treated (DC-PDC+) or untreated (3LL
controls) tumour-bearing mice. Supernatants were diluted 4-, 8-, 16-, 32-
or 64-fold. Data are the [3H]-thymidine incorporation into CTLL2 cells,
means ± s.d. (n = 3)
Table 3 Influence of polyamine deprivation on splenic IL-2 production.
Treatment Interleukin 2
(mU 10-7 spleen cells)
Healthy controls 124 ± 5
3LL controls 17± 7a
MDL 72527 39±9a
DFMO 44± 9a
NM-PDC 54 ± 1Oab
DC-PDC 60 ± 11ab
DC-PDC+ 98± 12b
Data were significantly different from healthy controls (ap< 0.01) and from
untreated 3LL grafted mice (bp< 0.05). Mice were treated with MDL 72527,
DFMO or with polyamine-deficient chow supplemented with neomycin and
metronidazole (NM-PDC), and inhibitors of polyamine metabolism (DC-PDC,
DC-PDC+) 1 week after graft. IL-2 production is expressed per 107 spleen
cells. Data are mean ± s.e.m. (n = 9).
lymphocyte populations were increased by 75% and T-CD8+
lymphocyte populations by 115% compared with untreated
tumour-bearing mice (Table 4). Consequently, the T-CD4+/T-CD8+
ratio in mice treated with DC-PDC or DC-PDC+ decreased to
reach normal value (Table 4).
Between the second and the third week after graft, the T-CD4+
lymphocyte population decreased by 20% (from 10.5% to 7.6%).
In contrast, the T-CD8+ lymphocyte population remained
unchanged (Figure 1). When polyamine deprivation was started 2
weeks after graft, at an advanced stage of tumour development
(0.79 ± 0.08 cm3), the tumour volume was not significantly
increased (0.93 ± 0.01 cm3) and T-CD4+ and T-CD8+ lymphocyte
populations were completely restored to normal values after 6
days of treatment (Figure 1). Spleen cells from mice treated at an
early or at an advanced stage of tumour development exhibited a
significant increase in both T-CD4+ and T-CD8+ lymphocyte popu-
lations compared with untreated tumour-bearing mice (Figure 1).
DISCUSSION
In the present study, we show that mice grafted with the 3LL carci-
noma exhibit a dramatic immune suppression: spleen cells show
both decreased spontaneous IL-2 production and decreased T-
CD4+ and T-CD8+ lymphocyte populations. In addition, the
polyamine content of the spleen was increased. By treating the
animals with a polyamine-deficient diet containing antibiotics and
inhibitors of polyamine metabolism (DC-PDC+), tumour growth
was greatly reduced and the immune-abnormalities were
completely reversed.
IL-2 production in spleen cells was enhanced in polyamine-
depleted mice compared with untreated tumour-bearing mice. By
reducing exogenous sources of the polyamines (polyamine-defi-
cient diet containing antibiotics: NM-PDC), IL-2 was significantly
overproduced. If selective specific inhibitors ofpolyamine metab-
olism (DFMO or MDL 72527) were given alone, IL-2 production
was not significantly enhanced, and when DFMO was combined
with NM-PDC (DC-PDC) no synergistic effect was observed. We
have previously shown that the reduction in exogenous sources of
polyamines (NM-PDC) exerts an anti-tumour effect and a signifi-
cant improvement in NK cytotoxic activity without affecting
polyamine concentrations in the tumour (Chamaillard et al, 1993).
We confirm in this study that exogenous sources of polyamines
can modulate the natural immune response.
The enhancement in IL-2 production was maximal when the
PAO inhibitor (MDL 72527) was added to treatment (DC-PDC+),
i.e. a total blockade ofall major polyamine sources was necessary
to obtain an optimal effect on spleen polyamine content and on
IL-2 production. This was also evident for NK-cell activity
(Chamaillard et al, 1993).
In contrast to what was observed with IL-2 and NK-cell activity,
the effect of the PAO inhibitor on the enhancement of the T
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Table 4 T-lymphocyte populations in the spleen oftumour-bearing mice after polyamine deprivation (early stage of tumour growth)
Treatment CD3+ T-CD4+ T-CD8+ T-CD4+lT-CD8+
Healthy controls 37.8 ± 1 14.6 ± 0.9 9.2 ± 0.5 1.7 ± 0.1
3LL controls 27.5 ± 1.4a 10.5± 0.7a 4.6 ± 0.3a 2.4 ± 0.3a
DC-PDC 42.9± 2b 18.3± 1.6b 10.1 ± 0.7b 2.0± 0.3
DC-PDC+ 43.5+ 1.8ab 18.5± 1.7b 10.4± 0.8b 1.8± 0.2b
Significantly different from healthy mice (ap< 0.005) and from 3LL grafted mice (bp < 0.005). Treatments started at an early stage of
tumour development (1 week after graft) and lymphocytes were analysed after 6 days of polyamine deprivation. The CD4 and CD8 T
cells were identified by double labelling: CD3/CD4 (T-CD4+) and CD3/CD8 (T-CD8+). Data are the percentage of cells expressing
differentiation markers (mean ± s.e.m. n = 12).
Table 5 Expression of the IL-2 receptor of the T-CD8+ lymphocytes after polyamine deprivation.
Treatment T-CD8+CD25+ T-CD8+CD25+1T-CD8+ Mean fluorescence
Healthy controls 1.6± 0.25 17.4 ±2.6 1.9 ± 0.1
3LL controls 0.8 ±0.1a 21.2 ± 3.6 2.1 ± 0.1
DC-PDC 2.1 ± 0.3b 22.4± 2.9 2.1 ± 0.1
DC-PDC+ 2.0 ± 0.2b 22.3 ± 3.5 2.2 ± 0.2
Significantly different from healthy controls with ap < 0.05 and from untreated 3LL grafted mice with bp < 0.05. Treatments started at an
early stage of tumour development (1 week after graft) and lymphocytes were analysed after 6 days of polyamine deprivation. Data are
the percentage of T-CD8+ cells expressing the IL-2 receptor (determined by triple labelling T-CD8+CD25+), and the mean of
fluorescence of the CD25-labelling (arbitrary units). Means ± s.e.m. (n = 12)
lymphocytes was not important: the augmentation of T-CD4+ and
T-CD8+ cells was similar in DC-PDC- or DC-PDC+-treated mice.
It is noteworthy that in tumour-bearing mice the decrease in T-
CD4+ and T-CD8+ lymphocyte populations is time and population
dependent. The most marked decrease (50% reduction) was
observed 3 weeks after graft forT-CD4+ and 2 weeks after graft for
the T-CD8+ population. This decrease is not due to lack of IL-2
receptor expression as in tumour bearing mice 22% of T-CD8+
cells were CD25 positive compared with 17% in healthy controls.
Irrespective of whether or not polyamine deprivation started at
an early or at an advanced stage of tumour growth (i.e. at a time
when immune suppression was established), T-CD4+ and T-CD8+
lymphocyte populations were completely restored to normal
values. This observation demonstrates that polyamine deprivation
not only prevents tumour-induced immune suppression, but also
is capable of reversing established immunological disorders.
However, the percentage of T-CD8+ cells expressing the IL-2
receptor in mice treated with DC-PDC or DC-PDC+ remained
unchanged. Thus, our treatment did not induce any specific activa-
tion ofcytotoxic T lymphocytes, but it enhanced their number.
One may speculate that the decrease in IL-2 production in
tumour-bearing mice is due to a relative decrease in the T-CD4+
lymphocyte population owing to the invasion by othercells into the
spleen (splenomegaly). This assumption is not correct, as the IL-2
production per 106 T-CD4+ cells was 85 mU for healthy controls
but only 16 mU for 3LL tumour-grafted mice. In mice deprived of
polyamines we found 50 mU IL-2 per 106 T-CD4+ cells.
The immune suppression observed in tumour-bearing animals
could be indirectly mediated by the induction of suppressor cells,
or directly by the secretion of immune-suppressive factors by
tumour cells. The induction of immune-suppressor cells by
tumour-derived colony-stimulating factors has been reported
(Young and Wright, 1992; Oghiso et al, 1993). During the early
phase of Lewis lung carcinoma growth, tumour cells stimulate
macrophages suppressing T-cell competence. This immune-
suppressor phase is PGE2 dependent (Ippoliti et al, 1985; Young et
al, 1985). In our study, changes in PGE2 plasma levels were not
observed during the early stage oftumour growth. Concerning the
immunosuppressive factors secreted by tumour cells, polyamine
deprivation treatment could have direct or indirect effects. As
polyamines play an important role in the proliferation and differ-
entiation processes, and as inhibition of polyamine metabolism
decreased protein synthetic activity (Rudkin et al, 1984; Holtta,
1985), polyamine deprivation could, by reducing tumour growth,
reduce the levels of immune-suppressive factors. However, the
reduction in the tumour burden had no major contribution to
immune restoration, as the T-CD8+ populations were significantly
different in treated and untreated mice with a similar tumour
volume (0.8-0.9 cm3, see Figure 1). Our findings show that
polyamine deprivation not only prevents the decrease in T-
lymphocyte populations but also reverses the tumour-induced
immune suppression; they are not in favour of an indirect effect
proportional to the tumour burden. One cannot exclude an influ-
ence ofpolyamine deprivation on tumour cell metabolism.
In our opinion the qualitative and quantitative modulation of
T-lymphocyte populations could be due to a direct effect of
polyamine deprivation on immune effector cells. Immune suppres-
sion has been reported to be associated with increased polyamine
levels (Flescher et al, 1992; Thomas et al, 1992). Thomas et al
observed in MRL-lpr/lpr lupus-prone mice, aberrations in thymic
maturation of T cells and increased putrescine and spermidine
levels. In this model the use of DFMO abolished the increase in
T-cell polyamine levels, and increased the number of cells with
the correct surface markers (Thomas et al, 1992).
Inhibition ofT-lymphocyte IL-2 production in mice grafted with
the 3LL Lewis lung carcinoma could be a consequence ofthe high
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polyamine levels in the spleen. Thomas et al (1993) reported the
blocking of the transmembrane Ca2+ influx in CD4-positive cells
by putrescine, a process essential for IL-2 production (Mills et al,
1985). This observation supports the idea that polyamine depriva-
tion could be directly responsible for the enhancement of IL-2
production by helper cells in the spleen. DC-PDC+ was the most
effective treatment, in agreement with the most complete depletion
of putrescine. The PAO inhibitor participated in the enhancement
of IL-2 production. In agreement with this observation are data
showing that the products of PAO activity induce a decrease in
both IL-2 mRNA levels and IL-2 production via suppression of
mitogen-induced transmembrane signalling (Flescher et al, 1994).
It seems very likely that polyamine deprivation in vivo has a
direct effect on the immune effector cells metabolism, as was
shown to be the case in vitro. As the reduction of exogenous
sources of polyamines exerts an anti-tumour effect without
affecting tumour polyamine content, it appears likely that the
enhancement of spontaneous IL-2 production, NK-cell activity
and T-lymphocyte populations contributes to the anti-tumoral
effect of the polyamine deprivation regimen. As numerous
immune cells are sensitive to IL-2, polyamine deprivation could
be of considerable interest in combination with anti-tumoral
immunotherapy trials.
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